Drug Discovery

Flow Chemistry in Drug Discovery

For the synthesis of compounds in pharmaceutical applications, it is important to select the most appropriate flow chemistry regime and equipment based on the goals of the application.

Recursion and Exscientia Merge, Create New Drug Discovery Company

US-headquartered biotech firm Recursion has announced that it will acquire UK-based pharmatech Exscientia in an all-stock deal. The transaction, which is expected to close in early 2025, would provide the combined entity with approximately $850 million in cash to fund its operations for the next three years. Reuters reported that Recursion will pay $688 million for the acquisition of Exscientia.

GSK and Flagship Pioneering Collaborate on Novel Medicines and Vaccines

GSK and innovation company Flagship Pioneering have entered a collaboration to develop a portfolio of new medicines and vaccines, starting in respiratory and immunology. Flagship’s ecosystem comprises 40 bioplatform companies, including Moderna.

Enzene Launches Drug Discovery Services Division

Enzene Biosciences, a global CDMO announces the launch of a new Drug Discovery Division.

AstraZeneca Granted Global Starmap AI License for Nanoform

Nanoform, a nanoparticle medical technology company, has awarded AstraZeneca a global online STARMAP license. STARMAP is an AI-based digital rendition of CESS technology, facilitating in-silico experiments for selecting molecules to be nanoformed. This license enables AstraZeneca to screen molecules during the entire drug development process.

Accelerated Drug Discovery

In January, Schrödinger, a provider of integrated software solutions, and the life sciences company Bayer announced a 5-year technology alliance to develop a comprehensive de novo design solution to accelerate the discovery of innovative, high-quality drugs.

Schrödinger and Bayer to Collaborate on Acceleration of Drug Discovery

Digital Transformation

Pharma: Adapting to an Ever-Changing Environment

East or West? East and West!

CatSci Appoints Paul Bradley as Head of Business Development

UK and Canada Link in Antibacterial Drug Project

GSK and Regeneron Back UK Biobank Project

Cancer Research UK and HitGen in Pact

Pfizer and IBM in e-Health Alliance

Novartis Axes Swiss and Chinese R&D Sites

Bayer and Evotec in Kidney Disease Pact

Bridging the Innovation Gap

Bayer and X-Chem Expand Drug Discovery Pact

Ipsen Pays $855 Million for Exelixis’ Cancer Drug

Johnson Matthey Acquires Pharmorphix

Fujifilm Holdings to Acquire Cellular Dynamics

CPhI Worldwide Announces International Advisory Board

Crown Bioscience Opens Oncology Center in North Carolina

Discovering the Future of Pharma

ChemOutsourcing: An Annual Cult Classic

Pharmaceutical Biotechnology: Drug Discovery and Clinical Applications

AMRI Further Expands Discovery Capabilities in India

“Lab-on-Chip” Drug Discovery & Development